5-LO/FLAP与冠心病相关性的研究进展

doi:10.3969/j.issn.1674-5817.2012.02.020

摘要/Abstract

摘要： 冠心病(CAD)是当今世界上严重威胁人类健康的心血管疾病之一。CAD的发病机制复杂,其中CAD是一种慢性炎症反应的观点已为广大学者所认同。白三烯(LTs)是重要的炎症介质,具有强烈的促炎作用。5-脂氧合酶(5-LO)是催化花生四烯酸(AA)生成LTs的关键酶,5-脂氧酶激活蛋白(FLAP)是5-LO氧化生成LTs过程中所必需的蛋白质。近年研究发现, 5-LO/FLAP级联, 在CAD的发病中具有重要作用。本文结合国内外文献,对5-LO/FLAP与冠心病的相关性研究做一综述。

关键词: 冠心病, 5-脂氧合酶, 5-脂氧酶激活蛋白, 白三烯, 炎症反应

Abstract: Coronary artery disease(CAD) is one of the cardiovascular disease that harmful to human health in the world nowadays. The pathogenesis of CAD is very complicated and until now it has not been completely clarified, the concept that CAD is a chronic inflammatory disease of the coronary artery, is now well accepted. Leukotrienes(LTs) are important inflammatory mediators, which play a strong role in promoting inflammatory reaction. 5-lipoxygenase (5-LO) is the key enzyme in the forming process of leukotrienes(LTs), while the 5-lipoxygenase activating protein(FLAP) is necessary if the 5-LO needs to be activated. Recent studies have found that 5-LO/FLAP play important roles in the formation and development of CAD. In this review, mainly focused on the relationship between 5-LO/FLAP and CAD.

Key words: Coronary Artery Disease, 5-lipoxygenase, 5-lipoxygenase activating protein, Leukotriene, Inflammation

中图分类号:

Q95-33

刘志华, 陈民利. 5-LO/FLAP与冠心病相关性的研究进展[J]. 实验动物与比较医学, 2012, 32(2): 170-174.

LIU Zhi-hua, CHEN Min-li. Advances in Research on Relationship between 5-LO/FLAP and Coronary Artery Disease[J]. Laboratory Animal and Comparative Medicine, 2012, 32(2): 170-174.

参考文献

[1] Hanson GK, Robertson AK, Soderberg-Naucler C.Inflammation and atherosclerosis[J]. Annu Rev Pathol, 2006, 1:297-329.
[2] Wang Q.Molecular genetics of coronary artery disease[J]. Curr Opin Cardiol, 2005, 20(3):182-188.
[3] Spanbroek R, Grabner R, Lotzer K, et al.Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis[J]. Proc Natl Acad Sci USA, 2003, 100(3):1238-1243.
[4] Merched AJ, Ko K, Gotlinger KH, et al.Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators[J]. FASEB J, 2008, 22(10):3595-3606.
[5] Hoshiko S, Radmark O, Samuelsson B.Characterization of the human 5-lipoxygenase gene promoter[J]. Proc Natl Acad Sci USA, 1990, 87(23):9073-9077.
[6] Dwyer JH, Hooman A, Dwyer KM, et al.Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis[J]. N Engl J Med, 2004, 350(1):29-37.
[7] Bennett CF, Chiang MY, Monia BP, et al.Regulation of 5-lipoxygenase and 5-lipoxygenase activating protein expression in HL-60 cells[J]. Biochem.J, 1993,289:33-39.
[8] Dixon RAF, Diehl RE, Opas E, et al.Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis[J]. Nature, 1990, 343(6225):282-284.
[9] Vickers PJ, O扤eill GP, Mancini JA, et al. Cross-species comparison of 5-lipoxygenase activating protein[J]. Mol.Pharmacol, 1992, 42:1014-1029.
[10] 刘峻豪, 孙凯, 白永怿, 等. Notch3基因多态、MTHFR基因多态和ALOX5AP基因多态的多位点联合交互作用显著增加血栓性脑卒中的风险[J]. 中国分子心脏病学杂志, 2008, 8(6):328-332.
[11] Qiu H, Johansson AS, Sjostrom M, et al.Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4[J]. Proc Natl Acad Sci USA, 2006, 103(18):6913-6918.
[12] Mehrabian M, Wong J, Wang X, et al.Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia[J]. Circ Res, 2001, 89(2):125-130.
[13] 张梅英, 吴红联, 杨葳, 等. 5-脂氧化酶转基因小鼠模型的制备[J]. 中国实验动物学报, 2010, 18(1):60-64.
[14] Mehrabian M, Allayee H, Wong J, et al.Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice[J]. Circ Res, 2002, 91(2):120-126.
[15] 李丽芳, 李晓霞, 滕晓云, 等. 5-脂氧化酶、白三烯在动脉粥样硬化大鼠主动脉中的表达[J]. 宁夏医学杂志, 2010, 3(12):1125-1127.
[16] 王崇泽, 曲毅, 方宁远, 等. 5 脂氧合酶在自发性高血压大鼠脑血管中的表达[J]. 中华高血压杂志, 2008, 16(10):915-918.
[17] Vidal C, Gomez-Hernandez A, Sanchez-Galan E, et al.Licofelone, a balanced Inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis[J]. JPET, 2007, 320(1):108-116.
[18] Ghosh S, Novak EM, Innis SM, et al.Cardiac proinflammatory pathways are altered with different dietary n-6 linoleic to n-3 α-linolenic acid ratios in normal, fat-fed pigs[J]. Am J Physiol Heat Circ Physiol 2007, 293:H2919-H2927.
[19] Tardif JC, L'Allier PL, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291(Atreleuton) in patients with recent acute coronary syndrome[J]. Cric Cardiovasc Imaging, 2010, 3:298-307.
[20] Motoyama S, Sarai M, Harigaya H, et al.Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome[J]. J Am Coll Cardiol, 2009, 54:49-57.
[21] Cipollone F, Mezzetti A, Fazia ML, et al.Association between 5-lipoxygenase expression and plaque instability in human[J]. Arterioscler Thromb VAsc Biol, 2005, 25(8):1665-1670.
[22] Zhao L, Moos MP, Grabner R, et al.The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm[J]. Nat Med, 2004, 10(9):966-973.
[23] 肖尧. MEF2A和ALOX5基因多态性与冠状动脉粥样硬化性心脏病的相关性研究[D]. 北京. 中国协和医科大学, 2006.
[24] Tsai MY.Interaction of dietary fatty acids with 5-lipoxygenase,ALOX5 activating protein with subclinical markers of coronary artery disease[A]. 5th Biologie Prospective Santorini Conference[C], Pers Med, 2011:227-242.
[25] Lorrain DS, Bain G, Correa LD, et al.Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation[J]. Eur J Pharmacol, 2010, 640(1-3):211-218.
[26] Back M, Sultan A, Hansson GK.5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation[J]. Circ Res, 2007, 100:946-949.
[27] Jawien J, Gajda M, Rudling M, et al.Inhibition of five lipoxygenase activating protein(FLAP) by MK-886 decreases atherosclerosis in apoE/lDLR-double knockout mice[J]. Eur J Clin Invest, 2006, 36(3):141-146.
[28] 徐晓伟, 盛文利, 刘琳. Pde4d和Alox5ap的mRNA水平与高血压性脑卒中和高血压病相关性的动物实验研究[J]. 中华医学遗传学杂志, 2007, 24(5):491-494.
[29] Zhou GY, Ge S, Liu DZ, et al.Atorvastatin Reduces Plaque Vulnerability in an Atherosclerotic Rabbit Model by Altering the 5-Lipoxygenase Pathway[J]. Cardiology, 2010, 115:221-228.
[30] Xu ZY, Azordegan N, Zhao ZH, et al.Pro-atherogenic effects of probucol in apo E-KO mice may be mediated through alterations in immune system: Parallel alteration in gene expression in the aorta and liver[J]. Atherosclerosis, 2009, 206(2):427-433.
[31] Helgadottir A, Manolescu A, Thorleifsson G, et al.The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke[J]. Nat Genet, 2004, 36(3):233-239.
[32] Koch W, Hoppmann P, Mueller JC, et al.No association of polymorphisms in the gene encoding 5-lipoxygenase activating protein and myocardial infarction in a large central European population[J]. Genet Med, 2007, 9(2):123-129.
[33] Girelli D, Martinelli N, Trabetti E, et al.ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study[J]. Eur J Hun Genet, 2007, 15(9):959-966.
[34] Tsai AK, Li N, Hanson NQ, et al.Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population[J]. Atherosclerosis, 2009(207):487-491.
[35] 张春燕, 郭玮, 吴炯, 等. 五脂氧化酶激活蛋白基因多态性及冠心病易患风险[J]. 中国临床医学, 2010, 17(5):631-634.
[36] Huang H, Zeng Z, Li J, et al.Variants of arachidonate 5-lipoxygenase-activating protein(ALOX5AP) gene and risk of coronary heart disease: a meta-analysis[J]. Arch Med Res, 2010, 41(8):634-641.